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Abstract
Purpose The transforming growth factor-beta (TGF-β) sig-
naling pathway is known to play a critical role in promoting
tumor growth. Consequently, blocking this pathway has been
found to inhibit tumor growth. In order to achieve an optimal
anti-tumor effect, however, it remains to be established wheth-
er blocking the TGF-β signaling pathway alone is sufficient,
or whether the tumor microenvironment plays an additional,
possibly synergistic, role.
Methods To investigate the relevance of blocking TGF-β
signaling in tumor cells within the context of their respective
tissue microenvironments, we treated a panel of patient-
derived xenografts (PDX) with the selective TGF-β receptor
kinase inhibitor LY2157299 monohydrate (galunisertib) and
assessed both the in vitro and in vivo effects.
Results Galunisertib was found to inhibit the growth in an
in vitro clonogenic assay in 6.3 % (5/79) of the examined
PDX. Evaluation of the expression profiles of a number of
genes, representing both canonical and non-canonical TGF-β
signaling pathways, revealed that most PDX exhibited expres-
sion changes affecting TGF-β downstream signaling. Next,
we subjected 13 of the PDX to an in vivo assessment and, by
doing so, observed distinct response patterns. These results
suggest that, next to intrinsic, also extrinsic or microenviron-
mental factors can affect galunisertib response. pSMAD2
protein expression and TGF-βRI mRNA expression levels
were found to correlate with the in vivo galunisertib effects.
Conclusions From our data we conclude that intrinsic, tumor-
dependent TGF-β signaling does not fully explain the anti-tumor
effect of galunisertib. Hence, in vivo xenograft models may be
more appropriate than in vitro clonogenic assays to assess the
anti-tumor activity of TGF-β inhibitors such as galunisertib.
Keywords Anti-tumor activity . Patient-derived
xenografts . TGF-β . Galunisertib . Gene expression
1 Introduction
The transforming growth factor beta (TGF-β) signaling path-
way plays a pleiotropic role in both normal and tumor tissues,
including tumor-stroma interactions [1, 2]. The canonical
TGF-β signaling pathway becomes activated when 1 of the
3 ligands (TGF-β1, TGF-β2, TGF-β3) binds to the TGF-β
receptor II (TGF-βRII), which subsequently heterodimerizes
with the TGF-β receptor I (TGF-βRI or ALK5) and
transphosphorylates the kinase domains of both receptors.
This phosphorylation step leads to a recruitment and phos-
phorylation of SMAD2 and SMAD3 (pSMAD2 and
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pSMAD3). Next, this complex initiates the canonical or
SMAD-dependent signaling cascade leading to nuclear trans-
location and downstream gene transcription [3]. In addition to
the canonical signaling pathway, other activation pathways
(non-canonical pathways) have been described, but these are
less understood [4]. The non-canonical or non-SMAD-
dependent activation of the TGF-β pathway includes signaling
via jun N-terminal kinase (JNK), p38 MAPK, ERK or MEKK.
In the past, several small molecule inhibitors targeting the
TGF-βRI serine/threonine kinase activity have been developed,
including LY2157299 monohydrate (galunisertib) [5], which
has been found to inhibit pSMAD2 expression in different
tumor models [6, 7]. Galunisertib is now being investigated
in a clinical trials and has very recently been shown to elicit
anti-tumor effects in patients with glioblastoma or hepatocellu-
lar carcinoma [8, 9]. Since only a few TGF-β inhibitors are
currently being studied in clinical trials, the development of
appropriate preclinical models is considered imperative in order
to reliably establish the mechanisms of action of TGF-β inhib-
itors and to specifically direct new drug screens.
In traditional models such as xenografts with established
tumor cell lines or in vitro cell viability studies, galunisertib
has shown moderate anti-tumor activity [10, 11]. Here, we used
patient-derived xenografts (PDX) instead of established tumor-
derived cell lines [12, 13]. In contrast to these cell lines, primary
patient-derived cells generally retain their original phenotype
[14, 15]. Initially, primary patient-derived cells were used to
assess the effects of cytotoxic agents [16] but, more recently,
these cells have also been found to be useful for characterizing
anti-tumor activities of cytostatic or immunomodulatory agents
[17–19]. It has also been noted that the effects of anti-tumor
drugs in PDX-based clonogenic assays correlated well with
clinical responses observed in patients with various solid cancers
[12, 20, 21]. Therefore, we hypothesized that PDX models
might be useful for testing both the in vitro and in vivo effects
of galunisertib in different primary tumor cell types and, as such,
to delineate the roles of both intrinsic and extrinsic activities of
TGF-β signaling in the respective responses in these models.
2 Materials and methods
2.1 Small molecule TGF-β receptor kinase inhibitor
The small molecule LY2157299 monohydrate (galunisertib),
targeting TGF-βRI serine/threonine kinase activity, was pro-
vided by Eli Lilly and Company, Indianapolis, USA.
Galunisertib was tested at concentrations ranging from 0.03
to 10.0 μM. Selected tumor xenografts were re-tested at
higher concentrations ranging from 1.0 to 80.0 μM. Stock
solutions of the compound were prepared in DMSO at 3.0 or
24.0 mM, respectively, and small aliquots were stored at
−20 °C in the dark. Final dilutions were prepared in Iscove’s
Modified Dulbecco’s Medium (IMDM, Life Technologies,
Carlsbad, CA) immediately prior to use.
2.2 In vitro clonogenic assays on patient-derived xenograft
samples
After obtaining the informed consent from patients and ap-
provals from local ethics review boards, patient-derived xe-
nograft (PDX) samples were derived from tumors subcutane-
ously growing as xenografts in NMRI nu/nu mice [13, 22]
purchased from Elevage Janvier, France or Taconic Europe,
Denmark. Details of the test procedure have been previously
described [21]. Briefly, solid tumor xenografts were removed
from mice under sterile conditions, mechanically disaggre-
gated and subsequently incubated in an enzyme cocktail
consisting of collagenase type IV (41 U/ml), DNase I (125
U/ml), hyaluronidase type III (100 U/ml) and dispase II (1.0
U/ml) in RPMI-1640 medium at 37 °C for 45–60 min. Single
cells were passed through sieves of 200 and 50 μm mesh size
and washed twice with sterile PBS. The percentage of viable
cells was determined in a hemocytometer using trypan blue
exclusion staining.
The tumor clonogenic assays were performed according to
a modified soft agar assay introduced by Hamburger &
Salmon [23]. Each test well contained three layers of equal
volumes: two layers of semi-solid medium (bottom and top
layer) and one layer of medium supernatent with or without
test compound. The bottom layer consisted of IMDM, sup-
plemented with 20 % (v/v) fetal calf serum (FCS, Sigma, St
Louis, MO), 0.01 % (w/v) gentamicin (Life Technologies,
Carlsbad, CA) and 0.75 % (w/v) agar (BD Biosciences, San
Jose, CA). Cells were seeded at a final density of 7.5×104 to
2×105 cells/ml using the same culture medium, supplemented
with 0.4 % (w/v) agar, and plated onto the bottom layer. The
test compound was added by continuous exposure (drug
overlay) in culture medium. Cultures were incubated at
37 °C and 7.5 % CO2 in a humidified atmosphere for 7–
20 days and monitored closely for colony growth using an
invertedmicroscope.Within this period, colonies were formed
with a diameter>50 μm. At the time of maximum colony
formation, counts were performed using an automatic image
analysis system (OMNICON 3600, Biosys GmbH, Germany)
after staining vital colonies for 24 h prior to evaluation with a
sterile aqueous solution of 2-(4-iodophenyl)-3-(4-nitrophe-
nyl)-5-phenyltetrazolium chloride (1 mg/ml, 100 μl/well)
[24]. Additionally, the viability of the colonies was deter-
mined using a CellTiter-Glo® viability assay (Promega,
Madison, WI), as an equivalent to colony formation, and
luminescence was measured using an EnVision® Xcite
Multilabel Reader (Perkin Elmer, Waltham, MA) to quantify
the amount of metabolically active and, thus, viable cells. All
assays were performed in a standardized manner and the
efficacy of galunisertib was assessed in relation to an
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untreated control only containing cells and the solvent
(DMSO at 0.3 %). The efficacy of galunisertib was rated
based on concentration-responses as: inhibition (T/C≤75 %),
no response (75 %<T/C<125 %) or stimulation (T/C≥
125 %).
2.3 In vivo assays on patient-derived xenografts
Patient-derived xenografts (PDX) were established from pri-
mary patient material as described above. Cell line-derived
xenografts were established from cells harvested from in vitro
culture. Xenografts were subcutaneously grown in nude mice
through serial passage and randomized after reaching tumor
volumes of approximately 72–120 mm3.
Galunisertib was prepared as a suspension in 1 % NaCMC,
0.5 % SLS, 0.05 % Antifoam, 0.085 % PVP C-30, and
administered twice daily for 14 days at a dose of 75 mg/kg
orally by gavage (12 mice per group). The control group
received an identical volume of the same mix without
galunisertib. The tumor load was determined by caliper mea-
surement twice weekly and the absolute tumor volume [mm3]
was calculated according to the formula: a [mm]×b2 [mm2]×
0.5, where (a) is the largest diameter and (b) is the perpendic-
ular diameter of the tumor representing an idealized ellipsoid.
The relative volume of an individual tumor on day x (RTVx)
was calculated by dividing the absolute volume [mm3] of the
respective tumor on day x (Tx) by the absolute volume of the
same tumor on the day of randomization, i.e., on day 0 (T0),
multiplied by 100: RTVx [%]=Tx/T0×100. Group median
RTVs were used for drawing tumor growth curves and for
treatment evaluation. The tumor growth response was
expressed quantitatively by the Area Between the Curves
(ABC), comparing the Area Under the Curve (AUC) of tumor
growth curves of the control group with the AUC of the group
treated with galunisertib according to the formula below.
ABC %ð Þ ¼ AUCcontrol−AUCtreatment
AUCcontrol
*100
Using this formula, positive ABC values represent tumor
growth curves below the control group and indicate growth
inhibition. Tumor responses were classified according to ABC
values of<−20 %=growth stimulation, −20 %<ABC<
20 %=no change, > 20 %=growth inhibition, compared to
the control. All studies were performed in agreement with
German animal welfare acts.
2.4 RNA isolation
For each untreated xenograft model, tissues were pooled from
4 different mice. Total RNA was extracted from frozen sam-
ples using the “mirVana miRNA Isolation kit” (Ambion,
Carlsbad, CA) according to the manufacturer’s instructions.
Genomic DNA was removed using the “RNase-free DNase
Set” (Qiagen, Hilden, Germany). The quality of the RNA
preparations was controlled using a Bioanalyzer (Agilent
Technologies, Palo Alto, CA). Only RNA samples with an
RNA integrity number (RIN)>6.5 were used for gene
expression profiling purposes (see below).
2.5 DNA isolation
For DNA isolation, snap frozen samples from untreated tu-
mors were digested with proteinase K at 55 °C overnight and
lysates were digested with RNase A (Qiagen). Next, DNAs
were extracted using phenol:chloroform:isoamylalcohol and
precipitated with ethanol. DNA pellets were washed and
resuspended in TElow buffer (Tris 10 mM pH8, EDTA
0.1 mM pH8). The integrity of the DNA samples was checked
after 1.3 % agarose gel electrophoresis, and the purity of the
DNA samples was determined using a NanoDrop 2000 sys-
tem (Thermo Scientific, Waltham, MA).
2.6 Gene expression profiling
Tota l RNAs were submi t ted to AROS Appl ied
Biotechnologies (Aarhus, Denmark) or DNA vision for anal-
ysis on Affymetrix HGU133 plus 2.0 gene expression arrays.
First- and second-strand synthesis, biotin labeling, fragmenta-
tion and hybridization were performed according to
Affymetrix protocols. Evaluation and normalization of the
Affymetrix GeneChip Data were performed in the “R” (ver-
sion 2.15.3) statistical computing environment. The hybrid-
izations were normalized using the gcRMA (gc robust
multichip averaging) method from Bioconductor to obtain
summary expression values for each probe set. One probeset
for each gene was chosen according to Li et al. [25]. Gene
expression levels were analyzed on a logarithmic scale and
were expressed in arbitrary units (U). Affymetrix expression
values<6 U were considered as background.
2.7 Gene mutation analyses
The mutation status of key cancer genes was assessed in all
samples using mass array sequencing panels from Sequenom,
Inc. (OncoCarta panels I, II and III) and then confirmed by
Sanger sequencing of individual exons or whole exome se-
quencing. Moreover, 64/79 PDX samples were profiled by
whole exome sequencing. Exonic regions from Oncotest
DNA samples were targeted using Agilent SureSelect
Human All Exon kits 38 MB (60 samples) or 51 MB (4
samples). Enriched genomic DNA was sequenced using an
Illumina HiSeq-2000 platform in 100 bp paired-end (PE)
reads and an expected coverage of ~80×. To remove the
mouse stroma content, PE reads that mapped better on the
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mouse (mm10) than on the human (hg19) genome were
discarded from the human mapped read dataset (based on
the Burrows-Wheeler Alignment mapping score) using
PicardTools. Variants were detected by independently using
3 different variant callers: the GATK’s UnifiedGenotyper, the
combination of Samtools mpileup and bcftools caller, and the
Freebayes caller. Only variants identified with all 3 tools,
showing a minimum number of variant-supporting reads of
3 and a minimum variant frequency of 5 %, were further
analyzed.
2.8 SNP profiling
The Affymetrix Genome-Wide Human SNP Array 6.0 with
1.8 million genetic markers, including more than 906,600
single nucleotide polymorphisms (SNPs) and more than
946,000 probes for the detection of copy number variation
(CNV), was employed using a standard protocol recommend-
ed by the manufacturer. According to the Affymetrix guide-
lines, contrast Quality Control (QC) and Median Absolute
Pairwise Difference (MAPD) thresholds were set at values>
0.4 and 0.35, respectively.
CNVs were identified using the Affymetrix Genotyping
Console™ v4.1 and the PICNIC software provided by the
Cancer Genome Project from the Welcome Trust Sanger
Institute [26].
2.9 Western blot analyses
Native tumor lysates were prepared for Western blotting as
previously described [17]. Briefly, 4 parts of untreated PDX
samples were homogenized using a Tissue Lyser (Qiagen) in
cell lysis buffer supplemented with Tris pH7.4 20 mM (Roth,
Karlsruhe, Germany), NaCl 100 mM (Merck, Darmstadt,
Germany), EDTA 1 mM (Sigma-Aldrich), NP40 1 %
(Sigma-Aldrich), deoxycholate 0.5 % (Sigma-Aldrich),
Na4O7P2 10H2O 10 mM (Sigma-Aldrich), Na3VO4 2 mM
(Sigma-Aldrich), NaF 20 mM (Sigma-Aldrich), PMSF
100 μM (Sigma-Aldrich), Benzonase 50 U/ml, and a protease
inhibitor mix 1× (Roche, Mannheim, Germany). Lysates were
cleared and protein concentrations measured (Protein Assay,
Bio-Rad, Berkley, CA). After polyacrylamide gel electropho-
resis and membrane transfer, the resulting membranes were
incubated with primary antibodies (anti- TGF-β1 clone 56E4,
Cat #3709, rabbit mAb, Cell Signaling, Beverly, CA; anti-
Smad2: clone D43B4, Cat #5339, rabbit mAb, Cell Signaling;
anti-pSmad2 (ser465/467): clone 138D4, Cat #3108, rabbit
mAb, Cell Signaling; anti-GAPDH: clone 14C10, Cat #2118,
rabbit mAb, Cell Signaling). The binding of primary antibod-
ies was detected using a secondary HRP-coupled antibody
(goat anti-rabbit IgG (H+L)-HRP conjugate, 170-6515-
Biorad), followed by incubation with an ECLWestern blotting
detection reagent (GE Healthcare Cat # RPN2106, Little
Chalfont, United Kingdom) and visualization using a GE
Healthcare Image Quant LAS 4000 CCD camera system
(GE Healthcare 28-9558-10). Quantification of protein ex-
pression was performed by subtracting the intensity of the
signal of GAPDH from the intensity of the signal of the
protein of interest, and was carried out using Image J software.
The calculated quantities of the respective proteins are
expressed in arbitrary units (AU). The Oncotest tumor lysate
pool containing a mixture of 380 different PDX lysates was
used as a normalization control to minimize plate-to-plate
variability.
3 Results
3.1 TGF-β inhibitor galunisertib variably impairs clonogenic
growth of tumor-derived xenografts
The TGF-β inhibitor galunisertib was evaluated in different
PDX and cell line-derived xenografts (CDX) in different test
series using a clonogenic assay. The test panel consisted of 11
different tumor types, including glioblastoma, melanoma, co-
lon, gastric, liver, non-small cell lung (adenocarcinoma, squa-
mous cell carcinoma and large cell lung carcinoma, NSCLC),
small cell lung, mammary, ovary, pancreas, and renal cell
cancers (Table 1). In addition, established cell lines derived
from hematologic malignancies including leukemia, lympho-
ma and myeloma were tested. Initial screens with diverse
numbers of tumor types have often been used to assess the
range of anti-tumor efficacy for compounds in order to under-
stand their differential activity [27–29]. The majority of PDX
in our current study were obtained from metastatic tumor
lesions (42/79, 53 %) and were poorly differentiated. Most
tumors were obtained frommales (46/79; 58 %) and the mean
age of the patients was 52 years (median age 55 years, range
11–82 years). The anti-tumor effects were recorded as inhibi-
tion of colony formation in relation to untreated controls (T/C
values, see materials and methods). Although doses above
10 μM are expected to be associated with unspecific activity
of galunisertib [6], we used higher concentrations to gain
insight into anti-tumor effects beyond the pharmacologically
targeted concentration.
The efficacy of galunisertib was assessed in a first series of
experiments in a panel of 66 tumor models. The compound
inhibited colony growth in 1/66 samples (1.5 %) in a
concentration-dependent manner when tested up to 10 μM.
Growth stimulation was observed in 15/66 (22.7 %) of the
samples and no response was seen in 50/66 (75.8 %) of the
samples. When tested up to 80 μM, galunisertib inhibited
colony growth in 5/24 (20.8 %) selected samples.
Stimulation of colony formation was observed in 10/24
(41.7 %) of these samples and no response was found in
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9/24 (37.5 %) of the samples (Fig. 1a). The most sensitive
xenograft samples were CXF 742 (colon cancer), LXFS 650
and LXFE 1422 (small cell lung cancer), and the hematologic
xenograft samples LYXF MYLA (T-ALL) and LYXF RAJI
(Burkitt’s lymphoma). No correlation between responses and
histopathological characteristics of the different samples was
observed (Fig. 1a).
We also assessed galunisertib in a second series of exper-
iments in panel of melanoma PDX (Fig. 1b). This melanoma
panel was chosen because of previous reports suggesting that
TGF-β1 signaling is an autocrine activation pathway for
tumor cell growth in melanoma [30–32]. We found that
galunisertib did not have any inhibitory effect in this panel
of melanoma xenografts, i.e., when tested up to 10 μM
galunisertib elicited no response in 12/17 (70.6 %) of the
samples, whereas stimulation of colony formation was ob-
served in 5/17 (29.4 %) of the samples. At a higher concen-
tration (30 μM), no response was observed in 11/17 (64.7 %)
of the samples, whereas stimulation of colony formation was
observed in 6/17 (35.3 %) of the samples.
3.2 Molecular characteristics of tumor models investigated
ex vivo
Because of the limited inhibitory effects observed in the
clonogenic assays, we set out to investigate whether the ca-
nonical TGF-β signaling pathway is altered in these PDX. To
this end, we assessed the expression level and mutation status
of genes associated with the canonical (i.e., the TGF-β1,
TGF-β2, SMAD2, SMAD3, SMAD4, SMAD7, TGF-βRI and
TGF-βRII genes) as well as the non-canonical (i.e., theMAPK
and AKT genes) TGF-β signaling pathways. The aimswere (i)
to characterize the molecular profiles of these pathways and
(ii) to evaluate whether the respective genes predicted drug
sensitivity.We also investigated the expression of two proteins
that were previously reported to be associated with TGF-β -
mediated drug resistance, i.e., TP53 and MED12 [33].
The copy numbers of the TGF-β1, TGF-β2, TGF-βR1 and
TGF-βR2 genes were assessed in 70/79 PDX samples. No
major rearrangements were observed. Two samples showed
mutations in TGF-β1: CXF 260, A350V and MEXF 989,
S138L. Two samples showed mutations in TGF-β2: CXF
269, S365R, and CXF 260, P387H. Three samples showed
mutations in TGF-βR1: MAXF 401, E242D, CXF 260,
A125V and LXFA 737, E111K. All these mutations were
found in the non-responder group. TGF-βR2 was mutated in
4 samples, including one from the group that showed growth
inhibition (LXFE 1422,153X [HGVS nomenclature for
frameshift]), one from the group that showed growth stimula-
tion (LXFA 1041, N384T) and two from the group that
showed no response (LXFA 526, 153X and CXF 1103,






























































































































































































































































































































































































































































































































































































































































































































Evaluating galunisertib in patient derived xenografts 137
mutation status of the PDX samples and the responses to
galunisertib (data not shown).
Next, we set out to investigate the mRNA expression levels
of the TGF-β1, TGF-β2, TGF-βR1 and TGF-βR2 genes in 77/
79 PDX samples (Fig. 2, Panel a). Heterogeneous mRNA
expression levels were found for these 4 genes in the samples
tested, and no significant associations were found between the
mRNA expression levels and the responses to galunisertib.
Despite this variability, however, some general trends were
observed: (i) the expression levels of the TGF-β1 and
TGF-β2 genes were generally low or undetectable, (ii) the
TGF-βR1 gene was well expressed in most of the samples
tested, whereas the TGF-βR2 gene was expressed at a low
level or undetectable in at least some of the samples (Fig. 2,
panel a).
We also assessed the status of the TGF-β1 downstream
canonical activation pathway (SMAD-dependent activation).
No major gene copy number alterations were found in the
samples tested, except in LXFA 749 (deletion of SMAD3) and
in LIXF 575 (deletion of SMAD4), both from the “stimulated”
group. Sequence analysis revealedmutations in SMAD1 (CXF
260, A262V, not shown) and SMAD2 (LXFE 397, S287C).
No mutations were found in SMAD3. SMAD4 was the most
frequently mutated gene with 9 mutations in samples from the
“no response” (7/9) and the “stimulated” (2/9) groups.
SMAD6 was mutated in 3 samples of the “inhibited” and the
“no response” groups (LXFS 650, L192P; CXF 260, D359G
and LXFA 1012, P323L; not shown). SMAD7 was mutated in
CXF 260 (A159Vand D113G) and MAXF 449 (R131C). All
SMAD genes (SMAD1, 2, 3, 4, 6 and 7) showed heteroge-
neous expression patterns, but these patterns were not found to
be associated with a response to galunisertib (Fig. 2). Of note,
SMAD7 expression was nearly absent inmost samples, where-
as SMAD2, SMAD3 and SMAD4 were expressed at similar
levels, with similar minimum to maximum ranges (Fig. 2b),
and variable patterns in most samples.
Subsequently, we subjected some non-canonical or
SMAD-independent genes [4, 33] to genomic and
transcriptomic analyses. No major genomic alterations in the
AKT1 gene were discovered, and AKT1 mRNA expression
was detected in most of the samples tested (range 5.5-11 Units
[U], mean 7.9 U). There was no significant association with
respons to galunisertib. The MAPK1 gene was found to be
expressed in 30 % of the samples investigated, and no asso-
ciations between its expression and galunisertib responses
were observed. E-cadherin (CDH1) expression levels were
observed in most of the samples tested (Fig. 3).
We next investigated the status of some genes presumed to
be associated with drug resistance in relation to TGF-β sig-
naling (Fig. 3). No overt MED12 gene copy number gains
were detected. In 21 samples, however, loss of one MED12
gene copy was noted without any observable alteration in
mRNA expression. MED12 gene mutations were detected in
8 samples, of which 6 exhibited mRNA expression levels that
were below the detection threshold. None of the alterations
observed were found to be associated with a galunisertib
response. Of note, TP53 mutations were frequently encoun-
tered in most of the samples tested (not shown), but these
mutations could not significantly be associated with responses
to galunisertib (Kruskal-Wallis p-value=0.13).
Based on the altered profiles observed in the TGF-β sig-






























-- inhibition; no response; -- stimulation
a b
Fig. 1 Responses of human PDX samples to galunisertib (LY2157299)
treatment assessed in an in vitro anchorage-independent growth assay. a)
Image analysis-based evaluation of colony formation revealed inhibition
(green lines), no response (blue lines) or stimulation (pink lines) of colony
formation across different tumor xenografts. b) Viability-based
evaluation of colony formation revealed no response (blue lines) or
stimulation (pink lines) of colony formation in patient-derived melanoma
xenografts. The efficacy of galunisertib was rated based on concentration-
response as: inhibition (T/C≤75%), no response (75%<T/C<125%), or
stimulation (T/C≥125 %)
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the pSMAD2 protein in order to substantiate the activated
status of the TGF-β signaling pathway (Fig. 4) in the PDX
samples before treatment. Most samples tested indeed showed
pSMAD2 expression, and in some cases this expression was
a
b
Fig. 2 Bar plot representing mRNA expression of genes associated with
the canonical TGF-β pathway using Affymetrix HGU133 plus2.0 arrays:
(a) TGF-β1 (yellow) and TGF-β2 (blue), and TGF-βR1 (yellow) and
TGF-βR2 (blue) and (b) SMAD2 (yellow) and SMAD3 (blue), and
SMAD4 (yellow) and SMAD7 (blue). The PDX samples are ranked by
their respective responses to galunisertib treatment, i.e., inhibited (green),
no response (yellow) or stimulated (pink). Grey bars indicate PDX mu-
tated for the gene of interest. For each gene, one probe-set was selected
according to Li et al. [25]. mRNA expression levels<6 were considered
as background and are not represented in this figure
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observed in spite of the fact that the TGF-βR1 protein levels
were either low or undetectable.
3.3 Galunisertib elicits in vivo anti-tumor activity
From the 79 samples included in this study, 13 were selected
for in vivo analyses. We used ABC calculations to assess the
efficacy of galunisertib treatment. By doing so, we found that
the ABC values ranked from −23.63 % (stimulation of tumor
growth) to 28.32% (inhibition of tumor growth) (Fig. 5a). The
mRNA expression levels of genes involved in the TGF-β
pathway were compared to the calculated ABC values
(Fig. 5a and b). Tumor growth inhibition was seen in 2 of 13
(15.4 %) selected samples (i.e., lung cancer PDX LXFA 737
and prostate cancer PDX PRXF MRIH 1579). No changes
were seen in 8/13 (61.5 %) samples. In 3/13 (23.1 %) samples,
tumor growth stimulation was observed. Next, we assessed a
possible association between the in vivo responses observed
and the concomitant TGF-β1 and SMAD2 gene expression
levels, or activation of the TGF-β signaling pathway by
measuring pSMAD2 protein levels (Fig. 5a and c). Although
the TGF-β1 and SMAD2 gene expression levels were not
associated with the in vivo response, high TGF-βRI transcript
levels and pSMAD2 protein levels were found to be correlated
with the in vivo anti-tumor responses (Spearman correlation
0.67, p-value=0.017 and Spearman correlation 0.68, p-val-
ue=0.025, respectively).
4 Discussion
In the present study, we observed in vitro and in vivo differ-
ences between the anti-tumor activities of the TGF-β receptor
Fig. 3 Bar plot representing mRNA expression of genes associated with
the non-canonical TGF-β pathway using Affymetrix HGU133 plus2.0
arrays: MAPK1 (yellow) and AKT1 (blue), and MED12 (yellow) and
CDH1 (blue). The PDX samples are ranked by their respective responses
to galunisertib treatment, i.e., inhibited (green), no response (yellow) or
stimulated (pink). Grey bars indicate PDX mutated for the gene of
interest. For each gene, one probe-set was selected according to Li et al.
[25]. mRNA expression levels<6 were considered as background and are
not represented in this figure
140 A. Maier et al.
kinase inhibitor galunisertib. We also observed a lack of broad
activity across the tumor panel tested, which is in stark con-
trast to other mostly cytotoxic anti-cancer agents. These ob-
servations are unusual for anti-cancer agents and, given the
activity of galunisertib observed in patients [8], we hypothe-
sized that the tissue microenvironment might play a critical
role in supporting TGF-β-dependent tumor growth. Our
current observations can be explained in several ways. First,
the activity of galunisertib in the tumor clonogenic assay may
be dependent on its selectivity. Galunisertib is known to
selectively target TGF-βRI (ALK5) at concentrations up to
1 μM [6, 34]. Concentrations above 10 μMare not considered
to be given to humans because of the possible toxic implica-














































































































































































































































































































































































































































































































































































































Fig. 4 Western blots showing TGF-β1, SMAD2 and pSMAD2 protein expression levels in 79 untreated PDX samples. GAPDH was used as loading
control. The Oncotest lysate pool (mix of protein from 380 PDX and CDX) was used in each Western blot as a normalization control

























NMA: Nude Mouse Assay
ABC: Area Between the Curves
Growth Inhibition: >20%


































Model NMA ABC values




LXFA 1012 -23,63 7,68 271,67
LXFA 749 -22,73 8,16 287,90
LXFA 1041 -20,69 8,47 105,53
LXFA 983 -19,45 9,23 446,68
LXFA 677 -10,41 8,28 261,64
SXF 463 -9,17 10,26 NA
MEXF 672 -6,54 11,24 2288,56
CXF 742 -4,64 9,37 340,51
LXFA CALU-6 -1,35 10,34 294,83
LXFA 526 0,46 9,05 449,72
LXFS 650 8,92 10,47 1450,80
PRXF MRI-H-1579 21,18 8,1 NA
LXFA 737 28,32 10,96 919,24
Fig. 5 Galunisertib activities in 13 PDX samples and its correlations
with TGF-βRI mRNA and pSMAD2 protein expression. (a) The
in vivo efficacies were evaluated by ABC (see materials and
methods) values and compared to TGF-βRI mRNA expression
(Affymetrix HGU133 Plus 2.0) and pSMAD2 protein expression
(Western blotting; see Fig. 4) levels. (b) Correlation between
TGF-βRI mRNA expression levels and ABC values (%). (c) Corre-
lation between pSMAD2 protein expression levels and ABC values.
P values≤0.05 are considered significant
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used concentrations up to 80 μM in order to assess its effects
beyond the pharmacological range. By doing so, we found no
overt differences between the higher and the lower concentra-
tions. Thus, the selectivity of the drug appeared to have little
or no effect in this study. Only 5 PDX showed small inhibitory
effects, not related to a specific tumor type. None of the other
tumors responded to galunisertib, including melanomas,
which are presumed to grow using a TGF-β-dependent auto-
crine loop. We grouped the galunisertib responses into three
categories: “inhibited”, “no response” or “stimulated”.
Second, we set out to understand why the majority of the
PDX either exhibited “no response” or a “stimulated” re-
sponse in vivo. Therefore, we assessed whether either the
canonical or the non-canonical TGF-β1signaling pathway
was intact. Canonical, SMAD-dependent TGF-β signaling
was found to be defective in 30 % of the PDX samples.
From this result we conclude that galunisertib may have acted
on kinases for which it was not designed, resulting in unspe-
cific activity in the clonogenic assays. TGF-βR1 and
TGF-βR2 transcripts were detected in most of the PDX sam-
ples, whereas TGF-β1 and TGF-β2 transcripts were only
detected at a low level and in half of the PDX. In such PDX
samples autocrine loops may be active, in spite of the fact that
the TGF-β1 and TGF-β2 levels were low. The SMAD1,
SMAD2 and SMAD4 genes were all expressed. Only the
SMAD4 gene was found to be frequently mutated, while the
others were rarely affected. Noteworthy, inhibitory effects of
galunisertib were observed in those samples that expressed the
TGF-βR1 and SMAD4 genes. Hence, the responses could not
be traced back to a specific or intact signaling pathway, either
canonical or non-canonical. Third, based on the clonogenic
assay, the anti-tumor activity of galunisertib or other agents
targeting the tumor microenvironment are underestimated
because such agents will not show cell killing, but will arrest
tumors by inhibition of cell migration and invasion [37–39]. It
is also possible that galunisertib targets signals that are not
tumor cell-dependent, such as immune- or other microenvi-
ronment signals, as has been shown in a syngeneic mouse
model in which a monoclonal antibody against TGF-βRII
showed anti-tumor activity [40]. This anti-tumor effect ap-
peared to be dependent on the presence of specific immune
cells such as CD8-positive T-cells and NK cells. We also
tested galunisertib in vivo in 13 of the PDX samples. Two of
these samples (LXFA 737 and PRXF MRIH 1579) showed
growth inhibition (Fig. 5, Fig. S1, S2, Table S1 and S2). Given
the presence of residual NK cell functions in nude mice, we
assume that in these two models blocking of TGF-β-
dependent signaling has facilitated NK activity against tumor
cells. In addition, we noted that the PDX samples investigated
contained variable amounts of human tumor cells and murine
stroma components, which may contain a fibroblast-rich mi-
croenvironment [41] or genomically instable tumor cells [42].
Although the amounts of stroma in the individual samples did
not directly correlate with the response rates in vivo, we found
that the presence of stroma not only affects the response rate in
general, but also that the in vivo response patterns correlated
better with the molecular characteristics of the PDX models
(i.e., pSMAD protein and TGF-βR1 mRNA expression).
In conclusion, it appears that models that reflect the normal
physiological condition, including all aspects of the microen-
vironment, are more useful to assess TGF-β1 inhibitors. In
absence of such models, results from such experiments must
be interpreted with caution.
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